GLP-1 drugs, such as the blockbuster medication Ozempic (semaglutide) are now widely used in the treatment of obesity as well as T2D, offering reduced cardiovascular and renal morbidity to these patients
In other words, that means someone who was able to reduce or even stop medication for conditions like high blood pressure or diabetes during treatment may see those conditions return if the underlying weight and metabolic drivers are no longer controlled
When this barrier breaks down, a condition researchers call intestinal permeability or "leaky gut," antigens that should stay in the gut escape into the bloodstream
Summary of phase 2 clinical trials of GLP1R agonists for PD Ex-4: exenatide-4, mTOR: mechanistic target of rapamycin, IRS1: insulin receptor substrate 1, MDS-UPDRS: Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale, PD: Parkinsons disease, PKB: protein kinase B, DAergic: dopaminergic, GLP1R: glucagon-like peptide-1 receptor.
Moreover, thyroid cancer risk was observed to be higher in obese people, and female patients with type 2 diabetes mellitus (T2DM) are more likely to have the extra-glandular invasion of PTC than male T2DM patients (126, 127)
